

## **Global Cell Therapy Manufacturing Market Report and Forecast 2023-2031**

Market Report | 2023-06-14 | 140 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

### **Report description:**

Global Cell Therapy Manufacturing Market Report and Forecast 2023-2031

Global Cell Therapy Manufacturing Market Outlook

The global cell therapy manufacturing market size was valued at USD 3.7 billion in 2022, driven by the increasing technological advancement in the cell therapies across the globe. The market size is anticipated to grow at a CAGR of 14.71% during the forecast period of 2023-2031 to achieve a value of USD 12.8 billion by 2031.

Cell Therapy Manufacturing: Introduction

Cell therapy is a rapidly evolving field in medicine that involves the use of living cells to treat various diseases and medical conditions. It holds great promise for regenerative medicine, immunotherapy, and other therapeutic applications. Cell therapy manufacturing refers to the process of manufacturing and producing these specialized cell-based therapies in a controlled and scalable manner.

Key Trends in the Global Cell Therapy Manufacturing Market

There are several key trends in the market and some of them are:

- **Advanced Manufacturing Technologies:** One of the key trends in cell therapy manufacturing is the development and adoption of advanced manufacturing technologies. This includes the use of automated systems, robotics, and closed-system manufacturing platforms to enhance the efficiency, reproducibility, and quality control of cell therapy production. Advanced manufacturing technologies help to streamline processes, reduce costs, and increase the scalability of cell therapy manufacturing.
- **Standardization and Quality Assurance:** With the increasing number of cell therapy products in development and clinical use, there is a growing focus on standardization and quality assurance in cell therapy manufacturing. Standardized protocols and manufacturing processes are being established to ensure consistent product quality, safety, and efficacy. Regulatory agencies are also providing guidelines and regulations to ensure compliance with good manufacturing practices (GMP) and quality control standards.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

-□Scale-Up and Commercialization: As cell therapies move from the research and development phase to commercialization, there is a need for scalable manufacturing processes to meet the increasing demand. Key trends in cell therapy manufacturing include the development of large-scale bioreactors, expansion technologies, and scalable manufacturing platforms to enable the efficient production of cell therapies at a commercial scale. This involves addressing challenges such as cell expansion, cell viability, and maintaining product consistency during scale-up.

-□Supply Chain and Logistics: The supply chain and logistics involved in cell therapy manufacturing are critical for ensuring the timely and safe delivery of cell therapies to patients. Key trends in this area include the development of specialized storage and transportation solutions, cryopreservation technologies, and cold chain management systems. These advancements help to maintain the viability and functionality of the cells during storage and transportation, ensuring their therapeutic efficacy upon administration.

-□Process Optimization and Cost Reduction: As cell therapy manufacturing becomes more widespread, there is a focus on process optimization and cost reduction. Manufacturers are continuously improving the efficiency of manufacturing processes, implementing process analytical technologies (PAT), and adopting innovative approaches to reduce production costs while maintaining product quality. This includes the development of more efficient cell culture media, bioprocess optimization strategies, and cost-effective manufacturing platforms.

## Global Cell Therapy Manufacturing Market Segmentations

### Market Breakup by Therapy Type

- T-Cell Therapies
- Dendritic Cell Therapies
- Tumor Cell Therapies
- Stem Cell Therapies
- Others

### Market Breakup by Technology

- Somatic Cell Technology
- Cell Immobilization Technology
- Viral Vector Technology
- Genome Editing Technology
- Cell Plasticity Technology
- 3D Technology
- Others

### Market Breakup by Source of Cell

- Autologous Cell
- Allogeneic Cell

### Market Breakup by Scale of Operation

- Preclinical
- Clinical
- Commercial

### Market Breakup by Applications

- Oncology
- Cardiovascular Diseases
- Orthopedic Diseases

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

-□Others

#### Market Breakup by End User

- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others

#### Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

#### Global Cell Therapy Manufacturing Market Scenario

The cell therapy manufacturing market is a rapidly growing sector within the healthcare industry. It involves the production of therapeutic cells that are used in the treatment of various diseases and conditions. Cell therapies offer promising solutions for diseases that have limited treatment options, such as cancer, autoimmune disorders, and genetic disorders.

The market for cell therapy manufacturing is driven by several factors. First and foremost, there is a growing demand for innovative and personalized therapies that can provide better treatment outcomes and improve patient quality of life. Cell therapies have shown remarkable efficacy in certain indications and have gained attention from healthcare providers, patients, and investors.

Another factor driving market growth is the advancements in cell therapy manufacturing technologies. This includes the development of closed-system manufacturing platforms, automation, and scalable bioreactors. These technologies enable efficient and cost-effective production of cell therapies, addressing the challenges of scalability and consistency in manufacturing. Overall, the cell therapy manufacturing market presents significant opportunities for companies involved in cell therapy research, development, and manufacturing. As more cell therapies enter clinical trials and gain regulatory approvals, the market is expected to experience substantial growth in the coming years. However, challenges such as high treatment costs, reimbursement issues, and complex manufacturing processes need to be addressed for the market to reach its full potential.

#### Global Cell Therapy Manufacturing Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Novartis AG
- F.Hoffmann La Roche AG
- Gilead Sciences, Inc.
- Thermo Fischer Scientific, Inc.
- Catalent, Inc.
- SR Life Sciences LLC (KBI Biopharma Inc)
- Waisman Center (Waisman Biomanufacturing)
- Cell and Gene Therapy Catapult
- Merck KGaA
- Lonza Group
- Oxford Biomedica Plc
- WuXi AppTec

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Charles River Laboratories International Inc.
- Institut Merieux (ABL Inc.)
- BioCentriq
- Centre for Commercialization of Regenerative Medicine (CCRM)
- Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics)
- Amgen Inc.
- Bluebird Bio Inc.
- Takeda Pharmaceutical Company Limited

\*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

## **Table of Contents:**

- 1□ Preface
- 1.1□ Objectives of the Study
- 1.2□ Key Assumptions
- 1.3□ Report Coverage - Key Segmentation and Scope
- 1.4□ Research Methodology
- 2□ Executive Summary
- 3□ Global Cell Therapy Manufacturing Market Overview
- 3.1□ Global Cell Therapy Manufacturing Market Historical Value (2016-2022)
- 3.2□ Global Cell Therapy Manufacturing Market Forecast Value (2023-2031)
- 4□ Global Cell Therapy Manufacturing Market Dynamics
- 4.1□ Market Drivers and Constraints
- 4.2□ SWOT Analysis
- 4.3□ Porter's Five Forces Model
- 4.4□ Key Demand Indicators
- 4.5□ Key Price Indicators
- 4.6□ Industry Events, Initiatives, and Trends
- 4.7□ Value Chain Analysis
- 5□ Global Cell Therapy Manufacturing Market Segmentation
- 5.1□ Global Cell Therapy Manufacturing Market by Therapy Type
- 5.1.1□ Market Overview
- 5.1.2□ T-Cell Therapies
- 5.1.3□ Dendritic Cell Therapies
- 5.1.4□ Tumour Cell Therapies
- 5.1.5□ Stem Cell Therapies
- 5.1.6□ Others
- 5.2□ Global Cell Therapy Manufacturing Market by Technology
- 5.2.1□ Market Overview
- 5.2.2□ Somatic Cell Technology
- 5.2.3□ Cell Immortalization Technology
- 5.2.4□ Viral Vector Technology
- 5.2.5□ Genome Editing Technology
- 5.2.6□ Cell Plasticity Technology
- 5.2.7□ 3D Technology

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.8 Others
- 5.3 Global Cell Therapy Manufacturing Market by Source of Cell
  - 5.3.1 Market Overview
  - 5.3.2 Autologous Cell
  - 5.3.3 Allogeneic Cell
- 5.4 Global Cell Therapy Manufacturing Market by Scale of Operation
  - 5.4.1 Market Overview
  - 5.4.2 Preclinical
  - 5.4.3 Clinical
  - 5.4.4 Commercial
- 5.5 Global Cell Therapy Manufacturing Market by Applications
  - 5.5.1 Market Overview
  - 5.5.2 Oncology
  - 5.5.3 Cardiovascular Diseases
  - 5.5.4 Orthopaedic Diseases
  - 5.5.5 Others
- 5.6 Global Cell Therapy Manufacturing Market by End User
  - 5.6.1 Market Overview
  - 5.6.2 Pharmaceutical and Biotechnology Companies
  - 5.6.3 Academic and Research Institutes
  - 5.6.4 Others
- 5.7 Global Cell Therapy Manufacturing Market by Region
  - 5.7.1 Market Overview
  - 5.7.2 North America
  - 5.7.3 Europe
  - 5.7.4 Asia Pacific
  - 5.7.5 Latin America
  - 5.7.6 Middle East and Africa
- 6 North America Cell Therapy Manufacturing Market
  - 6.1 Market Share by Country
  - 6.2 United States of America
  - 6.3 Canada
- 7 Europe Cell Therapy Manufacturing Market
  - 7.1 Market Share by Country
  - 7.2 United Kingdom
  - 7.3 Germany
  - 7.4 France
  - 7.5 Italy
  - 7.6 Others
- 8 Asia Pacific Cell Therapy Manufacturing Market
  - 8.1 Market Share by Country
  - 8.2 China
  - 8.3 Japan
  - 8.4 India
  - 8.5 ASEAN
  - 8.6 Australia
  - 8.7 Others

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9 Latin America Cell Therapy Manufacturing Market
  - 9.1 Market Share by Country
  - 9.2 Brazil
  - 9.3 Argentina
  - 9.4 Mexico
  - 9.5 Others
- 10 Middle East and Africa Cell Therapy Manufacturing Market
  - 10.1 Market Share by Country
  - 10.2 Saudi Arabia
  - 10.3 United Arab Emirates
  - 10.4 Nigeria
  - 10.5 South Africa
  - 10.6 Others
- 11 Patent Analysis
  - 11.1 Analysis by Type of Patent
  - 11.2 Analysis by Publication year
  - 11.3 Analysis by Issuing Authority
  - 11.4 Analysis by Patent Age
  - 11.5 Analysis by CPC Analysis
  - 11.6 Analysis by Patent Valuation
  - 11.7 Analysis by Key Players
- 12 Grants Analysis
  - 12.1 Analysis by year
  - 12.2 Analysis by Amount Awarded
  - 12.3 Analysis by Issuing Authority
  - 12.4 Analysis by Grant Application
  - 12.5 Analysis by Funding Institute
  - 12.6 Analysis by NIH Departments
  - 12.7 Analysis by Recipient Organization
- 13 Funding Analysis
  - 13.1 Analysis by Funding Instances
  - 13.2 Analysis by Type of Funding
  - 13.3 Analysis by Funding Amount
  - 13.4 Analysis by Leading Players
  - 13.5 Analysis by Leading Investors
  - 13.6 Analysis by Geography
- 14 Partnership and Collaborations Analysis
  - 14.1 Analysis by Partnership Instances
  - 14.2 Analysis by Type of Partnership
  - 14.3 Analysis by Leading Players
  - 14.4 Analysis by Geography
- 15 Regulatory Framework
  - 15.1 Regulatory Overview
    - 15.1.1 US FDA
    - 15.1.2 EU EMA
    - 15.1.3 INDIA CDSCO
    - 15.1.4 JAPAN PMDA

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.5□Others
- 16□Supplier Landscape
- 16.1□Novartis AG
  - 16.1.1□Financial Analysis
  - 16.1.2□Product Portfolio
  - 16.1.3□Demographic Reach and Achievements
  - 16.1.4□Mergers and Acquisitions
  - 16.1.5□Certifications
- 16.2□F.Hoffmann La Roche AG
  - 16.2.1□Financial Analysis
  - 16.2.2□Product Portfolio
  - 16.2.3□Demographic Reach and Achievements
  - 16.2.4□Mergers and Acquisitions
  - 16.2.5□Certifications
- 16.3□Gilead Sciences, Inc.
  - 16.3.1□Financial Analysis
  - 16.3.2□Product Portfolio
  - 16.3.3□Demographic Reach and Achievements
  - 16.3.4□Mergers and Acquisitions
  - 16.3.5□Certifications
- 16.4□Thermo Fischer Scientific, Inc.
  - 16.4.1□Financial Analysis
  - 16.4.2□Product Portfolio
  - 16.4.3□Demographic Reach and Achievements
  - 16.4.4□Mergers and Acquisitions
  - 16.4.5□Certifications
- 16.5□Catalent, Inc.
  - 16.5.1□Financial Analysis
  - 16.5.2□Product Portfolio
  - 16.5.3□Demographic Reach and Achievements
  - 16.5.4□Mergers and Acquisitions
  - 16.5.5□Certifications
- 16.6□JSR Life Sciences LLC (KBI Biopharma Inc)
  - 16.6.1□Financial Analysis
  - 16.6.2□Product Portfolio
  - 16.6.3□Demographic Reach and Achievements
  - 16.6.4□Mergers and Acquisitions
  - 16.6.5□Certifications
- 16.7□Waisman Center (Waisman Biomanufacturing)
  - 16.7.1□Financial Analysis
  - 16.7.2□Product Portfolio
  - 16.7.3□Demographic Reach and Achievements
  - 16.7.4□Mergers and Acquisitions
  - 16.7.5□Certifications
- 16.8□Cell and Gene Therapy Catapult
  - 16.8.1□Financial Analysis
  - 16.8.2□Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9 Merck KGaA
  - 16.9.1 Financial Analysis
  - 16.9.2 Product Portfolio
  - 16.9.3 Demographic Reach and Achievements
  - 16.9.4 Mergers and Acquisitions
  - 16.9.5 Certifications
- 16.10 Lonza Group
  - 16.10.1 Financial Analysis
  - 16.10.2 Product Portfolio
  - 16.10.3 Demographic Reach and Achievements
  - 16.10.4 Mergers and Acquisitions
  - 16.10.5 Certifications
- 16.11 Oxford Biomedica Plc
  - 16.11.1 Financial Analysis
  - 16.11.2 Product Portfolio
  - 16.11.3 Demographic Reach and Achievements
  - 16.11.4 Mergers and Acquisitions
  - 16.11.5 Certifications
- 16.12 WuXi AppTec
  - 16.12.1 Financial Analysis
  - 16.12.2 Product Portfolio
  - 16.12.3 Demographic Reach and Achievements
  - 16.12.4 Mergers and Acquisitions
  - 16.12.5 Certifications
- 16.13 Charles River Laboratories International Inc.
  - 16.13.1 Financial Analysis
  - 16.13.2 Product Portfolio
  - 16.13.3 Demographic Reach and Achievements
  - 16.13.4 Mergers and Acquisitions
  - 16.13.5 Certifications
- 16.14 Institut Merieux (ABL Inc.)
  - 16.14.1 Financial Analysis
  - 16.14.2 Product Portfolio
  - 16.14.3 Demographic Reach and Achievements
  - 16.14.4 Mergers and Acquisitions
  - 16.14.5 Certifications
- 16.15 BioCentriq
  - 16.15.1 Financial Analysis
  - 16.15.2 Product Portfolio
  - 16.15.3 Demographic Reach and Achievements
  - 16.15.4 Mergers and Acquisitions
  - 16.15.5 Certifications
- 16.16 Centre for Commercialization of Regenerative Medicine (CCRM)
  - 16.16.1 Financial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 16.16.2□Product Portfolio
- 16.16.3□Demographic Reach and Achievements
- 16.16.4□Mergers and Acquisitions
- 16.16.5□Certifications
- 16.17□Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics)
  - 16.17.1□Financial Analysis
  - 16.17.2□Product Portfolio
  - 16.17.3□Demographic Reach and Achievements
  - 16.17.4□Mergers and Acquisitions
  - 16.17.5□Certifications
- 16.18□Amgen Inc.
  - 16.18.1□Financial Analysis
  - 16.18.2□Product Portfolio
  - 16.18.3□Demographic Reach and Achievements
  - 16.18.4□Mergers and Acquisitions
  - 16.18.5□Certifications
- 16.19□Bluebird Bio Inc.
  - 16.19.1□Financial Analysis
  - 16.19.2□Product Portfolio
  - 16.19.3□Demographic Reach and Achievements
  - 16.19.4□Mergers and Acquisitions
  - 16.19.5□Certifications
- 16.20□Takeda Pharmaceutical Company Limited
  - 16.20.1□Financial Analysis
  - 16.20.2□Product Portfolio
  - 16.20.3□Demographic Reach and Achievements
  - 16.20.4□Mergers and Acquisitions
  - 16.20.5□Certifications
- 17□Global Cell Therapy Manufacturing Market - Distribution Model (Additional Insight)
  - 17.1□Overview
  - 17.2□Potential Distributors
  - 17.3□Key Parameters for Distribution Partner Assessment
- 18□Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19□Company Competitiveness Analysis (Additional Insight)
  - 19.1□Very Small Companies
  - 19.2□Small Companies
  - 19.3□Mid-Sized Companies
  - 19.4□Large Companies
  - 19.5□Very Large Companies
- 20□Payment Methods (Additional Insight)
  - 20.1□Government Funded
  - 20.2□Private Insurance
  - 20.3□Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Global Cell Therapy Manufacturing Market Report and Forecast 2023-2031**

Market Report | 2023-06-14 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottss-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scottss-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scottss-international.com

www.scottss-international.com